The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).
M. T. Seymour
Research Funding - Amgen; Roche
Other Remuneration - Roche
S. R. Brown
No relevant relationships to disclose
S. Richman
No relevant relationships to disclose
G. W. Middleton
No relevant relationships to disclose
T. Maughan
Honoraria - Pfizer
C. Olivier
No relevant relationships to disclose
S. J. Gwyther
No relevant relationships to disclose
J. Wadsley
No relevant relationships to disclose
I. Chau
Consultant or Advisory Role - Merck Serono (U)
Research Funding - Merck Serono
Other Remuneration - Pfizer
T. Hickish
No relevant relationships to disclose
L. K. Dawson
No relevant relationships to disclose
S. Falk
Consultant or Advisory Role - Amgen
A. O'Callaghan
Honoraria - Merck Serono; Roche
Other Remuneration - Merck Serono
K. Benstead
No relevant relationships to disclose
N. Wadd
No relevant relationships to disclose
A. Oliver
No relevant relationships to disclose
P. Chambers
No relevant relationships to disclose
H. Marshall
No relevant relationships to disclose
V. Napp
No relevant relationships to disclose
P. Quirke
Research Funding - Amgen